{
    "Trade/Device Name(s)": [
        "HemosIL AcuStar HIT-IgG(PF4-H)",
        "HemosIL AcuStar HIT Controls"
    ],
    "Submitter Information": "Instrumentation Laboratory Co.",
    "510(k) Number": "K170854",
    "Predicate Device Reference 510(k) Number(s)": [
        "K071255"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCO",
        "GGN"
    ],
    "Summary Letter Date": "March 21, 2017",
    "Summary Letter Received Date": "March 22, 2017",
    "Submission Date": "August 26, 2017",
    "Regulation Number(s)": [
        "21 CFR 864.7695",
        "21 CFR 864.5425"
    ],
    "Regulation Name(s)": [
        "Platelet factor 4 radioimmunoassay",
        "Plasma, Coagulation Control"
    ],
    "Analyte Class(es)": [
        "immunology",
        "hematology",
        "coagulation"
    ],
    "Analyte(s)": [
        "Anti-PF4/Heparin IgG antibodies"
    ],
    "Specimen Type(s)": [
        "Citrated plasma",
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ACL AcuStar"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CIA)"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control",
        "Calibrator",
        "Reagent Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for HemosIL AcuStar HIT-IgG(PF4-H) and HIT Controls, an automated chemiluminescent immunoassay for anti-PF4/heparin IgG antibody detection on ACL AcuStar platform",
    "Indications for Use Summary": "Qualitative, automated CIA for detection of IgG antibodies reacting with Platelet Factor 4 (PF4) complexed to heparin in adult patients suspected of HIT, using citrated plasma or serum on ACL AcuStar; controls for assay quality control",
    "fda_folder": "Hematology"
}